Author of the publication

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

, , , , and . Scientific reports, (2021)
DOI: 10.1038/s41598-021-93351-0

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancerTriple HER blockade in CRC, , , , , , , , , and 2 other author(s). Molecular Cancer Therapeutics, (2022)The eIg technology to generate Ig-like bispecific antibodies, , , and . mAbs, 14 (1): 2063043 (2022)Fc-based Duokines : dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc), , , , , , and . OncoImmunology, 11 (1): 2028961 (2022)A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells, , , , and . Scientific reports, (2021)Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release, , , and . Journal for ImmunoTherapy of Cancer, 9 (11): e003616 (2021)A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3, , , , , , , , , and 1 other author(s). mAbs, 13 (1): 1902034 (2021)eIg-based bispecific T-cell engagers targeting EGFR : Format matters, , , , , and . mAbs, 15 (1): 2183540 (2023)